Navidea Biopharmaceutica (Israel) Financial Diagnostics

NAVB -- Israel Stock  

ILS 98.00  12.00  10.91%

Navidea Biopharmaceuticals diagnostics interface makes it easy to digest most current publicly released information about Navidea Biopharmaceutica as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Navidea Biopharmaceutica price relationship with some important fundamental indicators such as market cap and management efficiency.

Navidea Biopharmaceutica Note

About 35.0% of the company shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 197.2. Navidea Biopharmaceuticals recorded loss per share of 0.11. This company had not issued any dividends in recent years. Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio. Navidea Biopharmaceutica is traded on Tel Aviv Stock Exchange in Israel. To find out more about NAVIDEA BIOPHAR contact Ricardo Gonzalez at 614-793-7500 or learn more at http://www.navidea.com.

Navidea Biopharmaceutica Alerts

Navidea Biopharmaceutica is not yet fully synchronised with the market data
Navidea Biopharmaceutica appears to be very risky and stock price may revert if volatility continues
The company reported revenue of 1.51 M. Net Loss for the year was (17.6 M) with profit before overhead, payroll, taxes, and interest of 1.81 M.
NAVIDEA BIOPHAR has accumulated about 2.21 M in cash with (10.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01.

Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 127.95 M.

Management Efficiency

Navidea Biopharmaceuticals has return on total asset (ROA) of (30.76) % which means that it has lost $30.76 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (128.87) % meaning that it generated substantial loss on money invested by shareholders.

Navidea Biopharmaceutica Technical and Predictive Indicators

Did you try this?

Run Companies Directory Now

   

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Companies Directory

Also Currentnly Active

Purchased over 200 shares of
few hours ago
Traded for 6.68
Purchased over 100 shares of
few hours ago
Traded for 11.39
Purchased over 200 shares of
few hours ago
Traded for 9.0
Please see also Stocks Correlation. Please also try Coins and Tokens Correlation module to utilize digital token correlation table to build portfolio of cryptocurrencies across multiple exchanges.
Search macroaxis.com